NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Exicure, Inc. (NYSE American:XCUR), is developing nucleic acid-based therapeutics to treat rare, severe genetic diseases and cancer. XCUR will be presenting at this year's virtual Fall Investor Summit on November 16th-18th.
The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.
About Exicure, Inc.
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based in Chicago, IL.
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
To register as a presenting company: please contact Brittney Blocker (email@example.com)
To request complimentary investor registration: please visit our website at www.investorsummitgroup.com
News Compliments of ACCESSWIRE
FOR MORE INFORMATION
Please visit: www.investorsummitgroup.com
Or, contact Brittney Blocker at firstname.lastname@example.org
SOURCE: Exicure, Inc.
View source version on accesswire.com: